Senseonics, a medtech manufacturer developing long-term, implantable continuous glucose monitoring (CGM) systems, and Ascensia Diabetes Care today announced FDA approval for the Eversense 365 CGM system for people with Type 1 and Type 2 diabetes aged 18 years and older. The company said Eversense 365 is the world’s first One Year CGM system.
In a social media landscape shaped by hashtags, algorithms, and viral posts, nurse leaders must decide: Will they let the narrative spiral, or can they adapt and join the conversation?
...
